295 related articles for article (PubMed ID: 37321827)
1. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
[TBL] [Abstract][Full Text] [Related]
2. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of
Zhao L; Niu B; Fang J; Pang Y; Li S; Xie C; Sun L; Zhang X; Guo Z; Lin Q; Chen H
J Nucl Med; 2022 Jun; 63(6):862-868. PubMed ID: 34556528
[TBL] [Abstract][Full Text] [Related]
4. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
[TBL] [Abstract][Full Text] [Related]
7. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
8. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
[No Abstract] [Full Text] [Related]
9. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Preclinical Evaluation of a Novel FAPI-04 Dimer for Cancer Theranostics.
Zhong X; Guo J; Han X; Wu W; Yang R; Zhang J; Shao G
Mol Pharm; 2023 May; 20(5):2402-2414. PubMed ID: 37015025
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
Millul J; Koepke L; Haridas GR; Sparrer KMJ; Mansi R; Fani M
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3050-3061. PubMed ID: 37261473
[TBL] [Abstract][Full Text] [Related]
12.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
Zhang P; Xu M; Ding J; Chen J; Zhang T; Huo L; Liu Z
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
[TBL] [Abstract][Full Text] [Related]
14. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
15. Design, Preclinical Evaluation, and Clinical Translation of
Zhao L; Pang Y; Fang J; Chen J; Zhou Y; Sun L; Wu H; Guo Z; Lin Q; Chen H
J Nucl Med; 2024 Mar; 65(3):394-401. PubMed ID: 38176714
[TBL] [Abstract][Full Text] [Related]
16. Radiosynthesis and First Preclinical Evaluation of the Novel
Wang C; Hu Z; Ding F; Zhao H; Du F; Lv C; Li L; Huang G; Liu J
Front Chem; 2022; 10():939160. PubMed ID: 35991604
[TBL] [Abstract][Full Text] [Related]
17.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
18. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
[TBL] [Abstract][Full Text] [Related]
19. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
20. 86Y-Labeled Albumin-Binding Fibroblast Activation Protein Inhibitor for Late-Time-Point Cancer Diagnosis.
Ding J; Xu M; Chen J; Zhang P; Huo L; Kong Z; Liu Z
Mol Pharm; 2022 Sep; 19(9):3429-3438. PubMed ID: 35976352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
